MUS81

Structure-specific endonuclease subunit MUS81 · Q96NY9 · MUS81 on Sugi Atlas →

9,134 patent compounds predicted against MUS81, 7,282 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Dynasore (SCHEMBL847982)	1.00	2/20
SCHEMBL1175103	0.78	2/20
SCHEMBL1175104	0.78	2/20
SCHEMBL1639414	0.70	2/20
SCHEMBL1639667	0.70	2/20
SCHEMBL1669454	0.69	2/20
SCHEMBL1173915	0.68	2/20
SCHEMBL684072	0.66	2/20
SCHEMBL1175077	0.66	2/20
SCHEMBL1175079	0.66	2/20
SCHEMBL1278987	0.63	2/20
SCHEMBL1278989	0.63	2/20
SCHEMBL1842722	0.52	2/20
Idarubicin (SCHEMBL4838)	1.00	1/20
Pirarubicin (SCHEMBL8323)	1.00	1/20
Pirarubicin (SCHEMBL8324)	1.00	1/20
Epigalocatechin Gallate (SCHEMBL35258)	1.00	1/20
Gallocatechin Gallate (SCHEMBL49461)	1.00	1/20
Epigalocatechin Gallate (SCHEMBL161547)	1.00	1/20
Gingkolic Acid (SCHEMBL163525)	1.00	1/20

Clinical trials — most relevant to MUS81 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial)	PHASE2	UNKNOWN
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies	PHASE1/PHASE2	RECRUITING
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA)	PHASE1/PHASE2	COMPLETED
A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations	PHASE2	RECRUITING
S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer	PHASE2	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma	PHASE1	WITHDRAWN
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers	PHASE1	COMPLETED
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer	PHASE1	COMPLETED
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
Study of the Effect of Innate on the Inflammatory Response to Endotoxin	nan	RECRUITING
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN
Immunohistochemical Expression of Excision Repair Cross Complementation Group 1 (ERCC1) in Laryngeal Squamous Cell Carcinoma and Its Correlation With Response to Radiotherapy.	nan	UNKNOWN
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease	nan	COMPLETED
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients	nan	ACTIVE_NOT_RECRUITING
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC	nan	UNKNOWN
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer	nan	UNKNOWN
Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581	nan	COMPLETED
Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews	nan	COMPLETED
Embryo DNA Repair Capacity Project	nan	COMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
Current Microsatellite Stability Results in Colon Cancer	nan	NOT_YET_RECRUITING
Large-scale COVID-19 Population Screening	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a MUS81 binder may also engage these)

Protein	Name	Similarity
Q91ZJ0	—	1.000	Q91ZJ0 →
Q4KM32	—	1.000	Q4KM32 →
Q56A04	—	0.988	Q56A04 →
Q7SXA9	—	0.987	Q7SXA9 →
Q640B4	—	0.985	Q640B4 →
Q9QXE2	—	0.985	Q9QXE2 →
Q5RKI3	—	0.984	Q5RKI3 →
Q66H85	—	0.984	Q66H85 →
Q9H8Y5	—	0.983	Q9H8Y5 →
Q8VDP3	—	0.983	Q8VDP3 →
Q9BYK8	—	0.983	Q9BYK8 →
Q4R380	—	0.983	Q4R380 →
Q9ESK3	—	0.982	Q9ESK3 →
Q002B5	—	0.982	Q002B5 →
P54777	—	0.982	P54777 →
POLL	DNA polymerase lambda	0.982	landscape →
Q9CR25	—	0.982	Q9CR25 →
FLAD1	FAD synthase	0.982	landscape →
Q8N8Q3	—	0.982	Q8N8Q3 →
Q86TL0	—	0.981	Q86TL0 →
Q58CQ5	—	0.981	Q58CQ5 →
Q9H611	—	0.981	Q9H611 →
Q8TDZ2	—	0.981	Q8TDZ2 →
Q99ML2	—	0.981	Q99ML2 →
Q643R3	—	0.981	Q643R3 →
O43542	—	0.981	O43542 →
RNF31	E3 ubiquitin-protein ligase RNF31	0.981	landscape →
E9QAM5	—	0.981	E9QAM5 →
Q924T7	—	0.981	Q924T7 →
Q7T0L4	—	0.981	Q7T0L4 →